| (CCTG) IND.238 | A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity | Dr Peter Ellis | Suspended/On hold | NCT03847649 |
| (Bold Therapeutics) BOLD-100-001 / TRIO039 | A Phase 1b Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours | Dr Elaine McWhirter | Open to recruitment | NCT04421820 |
| (GSK) GSK 224035 | A phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors. | Dr Courtney Coschi | Suspended/On hold | NCT07213609 |
| (GSK) 223054 / EMBOLD PanTumor-101 | A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumours | Dr Courtney Coschi | Open to recruitment | NCT06551142 |
Find a Trial
Contact Us